Placental Site Trophoblastic Tumor

Watchlist

(log in to enable)

Retrieved

2021-01-23

Source

Orphanet

Trials

—

Genes

CD274, AR, CGA, CGB5, CD276, VSIR, AKIRIN2, ZBTB7A, CKAP4, TP63, UVRAG, SLC22A4, RPE65, PAK1, INHA, HTC2, CGB3, CGB8

Drugs

—

Interested in hearing about new therapies?

Placental site trophoblastic tumor is a rare gestational trophoblastic tumor (GTT; see this term) which develops from the placental implantation site and always occurs following pregnancy, voluntary termination of pregnancy (VTP) or miscarriage.

Epidemiology

About 200 cases have been described in the literature.

Clinical description

Indicative signs are irregular metrorrhagia some time after spontaneous miscarriage or VTP, presence of metastasis or unexplained metrorrhagia in the weeks and months following normal childbirth or ectopic pregnancy.

Etiology

Etiology is unknown.

Diagnostic methods

Chorionic gonadotropin (hCG) levels are usually low at about 10 to 100 IU/l (N < 2 to 5 IU/l). Histologically, the myometrium is invaded by intermediate trophoblastic cells without chorionic villi and containing human placental lactogen hormone (hPL). Tissue necrosis is absent and hemorrhage is mild.

Management and treatment

Total hysterectomy is the basic treatment option.